NuCana plc American Depositary Share (NCNA)
Stock · NASDAQ · Health Care
$0.9901as of 10/16/2026
Price chart
Active signals
NCNA Signal Track Record
How signals performed across all stocks →What NCNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 23 | -9.8% | 26% | September 29, 2026 |
| Bollinger Band Breakout | 21 | -19.2% | 38% | August 28, 2026 |
| Volume Spike | 17 | -17.0% | 12% | September 30, 2026 |
| Any 20-session window (baseline) | -11.1% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cell…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 10
- Website
- www.nucana.com/
Fundamentals
- 1-day range
- $0.97$1.04
- Market cap
- $5.66M
- P/E (trailing)
- 0.01
- P/E (forward)
- -0.11
- EPS (trailing)
- $-0.00
- Dividend yield
- —
- Beta
- 2.44
- Avg. volume
- 120.0K
NuCana plc American Depositary Share Competitors
Chosen by industry and closest market cap.
- NCNANuCana plc American Depositary Share$0.99▼ 2.94%Market cap $5.66MP/E 0.01$0.9484$6.1
- CURXCuranex Pharmaceuticals Inc Common Stock$4.62▼ 4.35%Market cap $5.53MP/E —$3.58$16.94
- SILOSilo Pharma Inc. Common Stock$1.18▼ 1.67%Market cap $5.85MP/E —$1.3$10.44
- BGMSBio Green Med Solution Inc. Common Stock$0.91▲ 9.64%Market cap $5.35MP/E —$0.5664$6.11
- GOVXGeoVax Labs Inc. Common Stock$0.238▼ 7.75%Market cap $5.31MP/E —$0.24$15.75
- PULMPulmatrix Inc. Common Stock$1.36▼ 3.55%Market cap $6.06MP/E —$1.16$5.24
- GELSGelteq Limited Ordinary Shares$0.446▲ 3.48%Market cap $6.15MP/E —$0.387$2.01
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NCNA NuCana plc American Depositary Share | $5.66M | 0.01 | $0.99 | ▼ 2.94% | $0.9484$6.1 |
| CURX Curanex Pharmaceuticals Inc Common Stock | $5.53M | — | $4.62 | ▼ 4.35% | $3.58$16.94 |
| SILO Silo Pharma Inc. Common Stock | $5.85M | — | $1.18 | ▼ 1.67% | $1.3$10.44 |
| BGMS Bio Green Med Solution Inc. Common Stock | $5.35M | — | $0.91 | ▲ 9.64% | $0.5664$6.11 |
| GOVX GeoVax Labs Inc. Common Stock | $5.31M | — | $0.238 | ▼ 7.75% | $0.24$15.75 |
| PULM Pulmatrix Inc. Common Stock | $6.06M | — | $1.36 | ▼ 3.55% | $1.16$5.24 |
| GELS Gelteq Limited Ordinary Shares | $6.15M | — | $0.446 | ▲ 3.48% | $0.387$2.01 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Levy Elliott M. · June 19, 2026 · Disposition23.81M
- Bloss Jeffrey D. · June 19, 2026 · Disposition36.54M
- Bruce Theresa Margaret Ms · April 15, 2026 · Grant132.60M
Institutional Ownership
March 31, 2026
- Total shares held
- 56.5K
- Total value held
- $60.5K
- Institutional holders
- 8
- Unknown15.0K
- Unknown13.9K
- Unknown13.4K
- Unknown10.5K
- Unknown3.7K
- Unknown2
- Unknown2
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
NuCana Secures European Patent for NUC-7738
NuCana announced that the European Patent Office has granted a composition-of-matter patent for its drug candidate NUC-7738. This milestone strengthens the company's intellectual property position in Europe. The stock is currently trading near its 52-week low, reflecting the broader uncertainty often seen in early-stage biotech firms.
NuCana Secures European Patent for NUC-7738. NuCana announced that the European Patent Office has granted a composition-of-matter patent for its drug candidate NUC-7738. This milestone strengthens the company's intellectual property position in Europe. The stock is currently trading near its 52-week low, reflecting the broader uncertainty often seen in early-stage biotech firms.